Background: Intestinal mucositis is a most frequently occurring toxicity in cancer chemotherapy, and consequent malnutrition reduces tolerance to cancer therapies. Therefore it is important to lessen the severity of mucotitis and to develop complementary agents capable of reducing mucotitis-related symptoms. This study was conducted to determine 5-fluorouracil (5-FU) induced intestinal damage to understand intestinal damages due to chemotherapy and to provide information on biomarkers which can be used to screen complementary agents in future studies. Methods: BALB/c mice were divided into three experimental groups and subjected to the intraperitoneal injection of either 100 mg/kg or 200 mg/kg of 5-FU. The third group was used as PBS controls. Body weights and the consistency of the stools were recorded every day, and the animals were sacrificed on the 7th day post 5-FU administration. The expressions of intestinal tight junction proteins and mRNAs of tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β) were determined. Results: The body weight of the animals treated with 5-FU was significantly decreased in a dose-dependent manner. However, mice given 100 mg/kg 5-FU rapidly recovered the original body weight. Symptom of diarrhea was also more severe in 200 mg/kg 5-FU treated group than that of the 100 mg/kg 5-FU treated animals. The expressions of occludin and claudin-1, not ZO-1 protein expressions in 200 mg/kg 5-FU treated animals were significantly reduced compared to those of the control group or 100 mg/kg 5-FU group. The expression of Nuclear factor-kappa B p65 (NF-κB p65) protein and TNF-α mRNA were significantly higher in 5-FU treated group compared to those of control group. No difference was observed with IL-1β expression. Conclusions: These results suggested that selected tight junction proteins and inflammatory cytokines are related to 5-FU induced mucositis, and thereby can be used as targets of developing complementary agents. (J Cancer Prev 2013;18:322-329) 
INTRODUCTION
Gastrointestinal mucositis is a common side effect of anticancer chemotherapy that involves the small intestines. Not only does mucositis decrease the quality of life in most cancer patients because of its associated intense pain, it is also a high-risk factor for hematosepsis with neutropenia and malnutrition. This association, thus, renders mucositis a clinically important disease. Moreover, this specific side effect does not allow appropriate chemotherapy and radiotherapy, and becomes an obstacle that delays the administration of effective cancer treatment. 1 
5-Fluorouracil (5-FU) is an anticancer drug that is widely
used in the treatment of colorectal cancer, and it possesses a chemical structure similar to that of uracil and thymine. 2 A major part of it (more than 80%) is catabolized by hepatic dihydropyrimidine dehyrogenase (DPD), whereas the rest induces cell death by inhibiting RNA and DNA syntheses through fluorodeoxyuridine monophosphate (FdUMP) and fluorouridine triphosphate (FUTP). 3, 4 The major side effects of 5-FU include myelosuppression, diarrhea, cardiotoxicity, dermatitis, and mucositis. 5, 6 Of these, gastrointestinal mucositis has been reported in approximately 80% of patients who have received cancer treatment by using MATERIALS AND METHODS
Experimental animals
Nine, white, 6-week-old BALB/c male mice, obtained from the Central Laboratory Animals, Seoul, Korea, were utilized in this study. After 1 week of acclimatization, the mice were randomly classified into 3 groups, with 3 mice in each group. Phosphate-buffered saline (PBS) solution was administered to the control group, and 100 mg/kg and 200 mg/kg of 5-FU dissolved in PBS were injected intraperitoneally to the 2 experimental groups, respectively (Fig. 1) .
The mice were kept in a room maintained at a temperature of 24±2 o C, relative humidity of 60±5%, and a dark cycle of 12 h. Weight and diarrhea scores were measured daily in all mice starting from the day of 5-FU administration.
Sample collection and pretreatment
Once the treatment period was completed, the mice were fasted for 12 h and anesthetized using Zoletil solution diluted in a saline solution, followed by longitudinal laparotomy. Liver and spleen were isolated and washed in PBS. After pat drying the tissues, their weights were measured and stored at −80 o C. The small and large intestines were separated and their lengths were measured.
Mucous were scraped and stored at −80 o C. Tight junction (TJ) protein expression and cytokine secretion were also measured.
Diarrhea assessment
The presence or absence and degree of diarrhea were determined based on the standards established for the diarrhea assessment. 8 The diarrhea score was assessed 
Protein expression by western blot analysis
Small intestine tissues were homogenized using the protein extraction reagent PRO-PREP TM (Intronbio, Sungnam, South Korea), and were subjected to centrifugation (13,000 rpm, 10 min, 4 o C) after keeping on ice for 20 min.
The extracted proteins were quantified using a Protein Table 1 . Heights, IL, USA). The intensities of the bands were measured using LAS3000 (Fujifilm, Tokyo, Japan).
RNA isolation and real-time quantitative PCR analysis
The levels of mRNA expression of TNF-α and IL-1β in the small intestines were analyzed using real-time quantitative polymerase chain reaction (qPCR). Trizol ( 
RESULTS

Body weight changes and main organ weight
Body weight changes in the experimental animals are shown in Fig. 2 . Compared to the control group, the extent of body weight reduction in the experimental groups manifested significant differences from Day 1 after the 5-FU administration ( Fig. 2A, P＜0 .05). Significantly higher reduction in the body weight was observed in the group administered with 200 mg/kg of 5-FU compared to the 100 mg/kg group ( Fig. 2A) . The weights of the liver and kidney and the lengths of the small and large intestines are presented in Table 2 . The weight of the spleen significantly decreased in the 5-FU treated experimental groups (P＜0.05). No significant differences in the weight of the liver and lengths of the small and large intestines were observed.
Diarrhea assessment
The most common symptom of gastrointestinal mucositis is diarrhea. Treatment with 5-FU significant increased the cumulative diarrhea score from Day 3 after the 5-FU administration (Fig. 2B, P＜0 .05). Significant differences were also observed between the 100 mg/kg and 200 mg/kg groups (P＜0.05) from Day 6 after the 5-FU administration (Fig. 2B, P＜0 .05).
Claudin-1, occludin, and ZO-1 expressions of the mucous of the small intestine
The protein expression levels of claudin-1, occludin, and zonula occludens-1 (ZO-1) involved in gastrointestinal per- (Fig. 3, P＜ 0.05), whereas those of occludin and ZO-1 did not show significant differences.
4. NF-κB p65 protein expression in the mucous of the small intestine NF-κB is a critical transcription factor in inflammatory responses. NF-κB protein expression in the mucous of the small intestine was significantly higher in both the groups compared to that in the control (Fig. 4, P＜0 .005). The expression level was slightly lower in the group in which high concentration of 5-FU was used compared to that in the low concentration (Fig. 4, P＜0 .05).
TNF-α and IL-1β mRNA expressions in the mucous of the small intestine
The levels of mRNA expression of TNF-α and IL-1β, which are pro-inflammatory cytokines, were analyzed in the mucous of the small intestine. TNF-α showed a 98% increased expression in the group treated with 200 mg/kg 5-FU compared to the control group (Fig. 5, P＜0 .005).
IL-1β showed a 32% increased expression in the group administered 200 mg/kg of 5-FU, although there was not statistically significant (Fig. 5) . In conclusion, 5-FU treated animals revealed significant body weight loss in a dose-dependent manner. Clear and significant TJ protein losses are observed suggesting appropriate intervention towards these targets may alleviate chemotherapy-associated mucositis.
